Role of histone modification in 12‑lipoxygenase‑associated p21 gene regulation

Cui,Yingchun; Liu,Nian; Ma,Fuzhe; Sun,Weixia; Wu,Hao; Xu,Zhonggao; Yuan,Hang

doi:10.3892/mmr.2016.5724

Role of histone modification in 12‑lipoxygenase‑associated p21 gene regulation

Authors:
- Yingchun Cui
- Nian Liu
- Fuzhe Ma
- Weixia Sun
- Hao Wu
- Zhonggao Xu
- Hang Yuan
View Affiliations

Affiliations: Department of Nephrology, Second Affiliated Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Center of Urology, First Affiliated Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Department of Nephrology, First Affiliated Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: September 6, 2016 https://doi.org/10.3892/mmr.2016.5724
Pages: 3978-3984

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to examine the impacts and mechanisms of 12‑lipoxygenase (12‑LO) and its metabolites on the acetylation and methylation of histone‑3‑lysine (H3K) in the p21 gene. Rat mesangial cells (MCs) were selected for use in the present study. A chromatin immunoprecipitation assay, reverse transcription‑quantitative polymerase chain reaction analysis and a luciferase assay were used to detect transcriptional activities, the acetylation (Ac) of H3K (H3KAc), p21 promoter methylation (Me) and the transcription regions induced by 12 (S)‑hydroxyeicosatetraenoic acid (HETE). The cells were transfected to induce the overexpression of p300 to examine changes in 12 (S)‑HETE‑associated p21 regulation and epigenetic modifications. 12 (S)‑HETE enhanced p21 transcriptional activity and mRNA expression. In the promoter regions, P1 and P2, and the T1 transcription region, 12 (S)‑HETE induced significant H3K9 Ac and H3K4 Me1 epigenetic modifications, however, no changes were observed in the T2 region. By contrast, 12 (S)‑HETE treatment markedly prevented H3K9Me3 at the p21 promoter, suggesting that complex Me was involved in 12 (S)‑HETE‑associated p21 regulation. Furthermore, the overexpression of p300 markedly enhanced basal and 12 (S)‑HETE‑associated p21 transcriptional regulation in the MCs. 12 (S)‑HETE treatment also induced histone acetyltransferase p300 occupancy in the p21 promoter, and reduced the nuclear expression and occupancy of lysine‑specific demethylase (LSD1) in the p21 promoter. 12 (S)‑HETE induced p300 occupancy, and reduced the nuclear expression and occupancy of LSD1 in the p21 promoter. Therefore, enhanced H3K9Ac and H3K4Me1 in the p21 promoter and transcription regions, and decreased H3K9Me3 in the p21 promoter increased the expression of p21.

View Figures

View References

1	Hostetter TH: Progression of renal disease and renal hypertrophy. Annu Rev Physiol. 57:263–278. 1995. View Article : Google Scholar : PubMed/NCBI
2	Al-Douahji M, Brugarolas J, Brown PA, Stehman-Breen CO, Alpers CE and Shankland SJ: The cyclin kinase inhibitor p21WAF/CIP1 is required for glomerular hypertrophy in experimental diabetic nephropathy. Kidney Int. 56:1691–1699. 1999. View Article : Google Scholar : PubMed/NCBI
3	Bleich D, Chen S, Zipser B, Sun D, Funk CD and Nadler JL: Resistance to the type 1 diabetes induction in 12-lipoxygenase knockout mice. J Clin Invest. 103:1431–1436. 1999. View Article : Google Scholar : PubMed/NCBI
4	Yuan H, Lanting L, Xu ZG, Li SL, Swiderski P, Putta S, Jonnalagadda M, Kato M and Natarajan R: Effects of cholesterol tagged small interfering RNA targeting 12/15-lipoxygenase on parameters of diabetic nephropathy in mouse model of type 1 diabetes. Am J Physiol Renal Physiol. 295:F605–F617. 2008. View Article : Google Scholar : PubMed/NCBI
5	Ma J, Natarajan R, LaPage J, Lanting L, Kim N, Becerra D, Clemmons B, Nast CC, Surya Prakash GK, Mandal M and Adler SG: 12/15-lipoxygenase inhibitors in diabetic nephropathy in the rat. Prostaglandins Leukot Essent Fatty Acids. 72:13–20. 2005. View Article : Google Scholar
6	Kim YS, Xu ZG, Reddy MA, Li SL, Lanting L, Sharma K, Adler SG and Natarajan R: Novel interactions between TGF-{beta}1 actions and the 12/15-lipoxygenase pathway in mesangial cells. J Am Soc Nephrol. 16:352–362. 2005. View Article : Google Scholar
7	Kato M and Natarajan R: Diabetic nephropathy-emerging epigenetic mechanisms. Nat Rev Nephrol. 10:517–530. 2014. View Article : Google Scholar : PubMed/NCBI
8	Reddy MA, Tak Park J and Natarajan R: Epigenetic modifications in the pathogenesis of diabetic nephropathy. Semin Nephrol. 33:341–353. 2013. View Article : Google Scholar : PubMed/NCBI
9	Reddy MA, Sumanth P, Lanting L, Yuan H, Wang M, Mar D, Alpers CE, Bomsztyk K and Natarajan R: Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic db/db mice. Kidney Int. 85:362–373. 2014. View Article : Google Scholar :
10	Natarajan R: Drugs targeting epigenetic histone acetylation in vascular smooth muscle cells for restenosis and atherosclerosis. Arterioscler Thromb Vasc Biol. 31:725–727. 2011. View Article : Google Scholar : PubMed/NCBI
11	Yuan H, Reddy MA, Sun G, Lanting L, Wang M, Kato M and Natarajan R: Involvement of p300/CBP and epigenetic histone acetylation in TGF-β1-mediated gene transcription in mesangial cells. Am J Physiol Renal Physiol. 304:F601–F613. 2013. View Article : Google Scholar
12	Kato M, Dang V, Wang M, Park JT, Deshpande S, Kadam S, Mardiros A, Zhan Y, Oettgen P, Putta S, et al: TGF-β induces acetylation of chromatin and of Ets-1 to alleviate repression of miR-192 in diabetic nephropathy. Sci Signal. 6:ra432013. View Article : Google Scholar
13	Sun G, Reddy MA, Yuan H, Lanting L, Kato M and Natarajan R: Epigenetic histone methylation modulates fibrotic gene expression. J Am Soc Nephrol. 21:2069–2080. 2010. View Article : Google Scholar : PubMed/NCBI
14	Villeneuve LM and Natarajan R: The role of epigenetics in the pathology of diabetic complications. Am J Physiol Renal Physiol. 299:F14–F25. 2010. View Article : Google Scholar : PubMed/NCBI
15	Reddy MA, Zhang E and Natarajan R: Epigenetic mechanisms in diabetic complications and metabolic memory. Diabetologia. 58:443–455. 2015. View Article : Google Scholar :
16	Miao F, Chen Z, Genuth S, Paterson A, Zhang L, Wu X, Li SM, Cleary P, Riggs A, Harlan DM, et al: Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes. Diabetes. 63:1748–1762. 2014. View Article : Google Scholar : PubMed/NCBI
17	Ling C and Groop L: Epigenetics: A molecular link between environmental factors and type 2 diabetes. Diabetes. 58:2718–2725. 2009. View Article : Google Scholar : PubMed/NCBI
18	Pirola L, Balcerczyk A, Okabe J and El-Osta A: Epigenetic phenomena linked to diabetic complications. Nat Rev Endocrinol. 6:665–675. 2010. View Article : Google Scholar : PubMed/NCBI
19	Marmorstein R and Trievel RC: Histone modifying enzymes: Structures, mechanisms, and specificities. Biochim Biophys Acta. 1789:58–68. 2009. View Article : Google Scholar
20	Shilatifard A: Chromatin modifications by methylation and ubiquitination: Implications in the regulation of gene expression. Annu Rev Biochem. 75:243–269. 2006. View Article : Google Scholar : PubMed/NCBI
21	Sun G, Reddy MA, Yuan H, Lanting L, Kato M and Natarajan R: Epigenetic histone methylation modulates fibrotic gene expression. J Am Soc Nephrol. 21:2069–2080. 2010. View Article : Google Scholar : PubMed/NCBI
22	Reed SM and Quelle DE: p53 Acetylation: Regulation and consequences. Cancers (Basel). 7:30–69. 2014. View Article : Google Scholar
23	Marouco D, Garabadgiu AV, Melino G and Barlev NA: Lysine-specific modifications of p53: A matter of life and death? Oncotarget. 4:1556–1571. 2013. View Article : Google Scholar : PubMed/NCBI
24	Lee JT and Gu W: SIRT1: Regulator of p53 deacetylation. Genes Cancer. 4:112–117. 2013. View Article : Google Scholar : PubMed/NCBI
25	Shi Y, Sawada J, Sui G, Affar el B, Whetstine JR, Lan F, Ogawa H, Luke MP, Nakatani Y and Shi Y: Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature. 422:735–738. 2003. View Article : Google Scholar : PubMed/NCBI
26	Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA and Shi Y: Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 119:941–953. 2004. View Article : Google Scholar : PubMed/NCBI
27	Wang H, Cao R, Xia L, Erdjument-Bromage H, Borchers C, Tempst P and Zhang Y: Purification and functional characterization of a histone H3-lysine 4-specific methyltransferase. Mol Cell. 8:1207–1217. 2001. View Article : Google Scholar
28	Nishioka K, Chuikov S, Sarma K, Erdjument-Bromage H, Allis CD, Tempst P and Reinberg D: Set9, a novel histone H3 methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation. Genes Dev. 16:479–489. 2002. View Article : Google Scholar : PubMed/NCBI